NFATC2 and mesenchymal chondrosarcoma: Yoshida et al. first reported NKX3.1 expression in 9/11 (82%) of EWSR1-NFATC2 sarcomas using a polyclonal antibody, consistent with transcriptomic analyses, as well as 9/9 mesenchymal chondrosarcomas [96].